Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)54

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)34

Views

Views
January 20250
February 20252
March 202516
April 20253
May 20254
June 20259
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States8
Argentina2
Barbados1
Brazil1
Spain1
France1
United Kingdom1
Paraguay1
Turkey1
 

Top cities views

Views
Abington1
Angers1
Ankara1
Cleveland1
Council Bluffs1
Denver1
Durban1
Jundiaí1
Lomas de Zamora1
Saint Michael1